1.Wnt5a stimulates chemotactic migration and chemokine production in human neutrophils.
Young Su JUNG ; Ha Young LEE ; Sang Doo KIM ; Joon Seong PARK ; Jung Kuk KIM ; Pann Ghill SUH ; Yoe Sik BAE
Experimental & Molecular Medicine 2013;45(6):e27-
		                        		
		                        			
		                        			Wnt5a is a ligand that activates the noncanonical Wnt signaling pathways (beta-catenin-independent pathways). Human neutrophils expressed several Wnt5a receptors, such as Frizzled 2, 5 and 8. Stimulation of human neutrophils with Wnt5a caused chemotactic migration and the production of two important chemokines, CXCL8 and CCL2. CCL2 production by Wnt5a was mediated by a pertussis toxin-sensitive G-protein-dependent pathway. Wnt5a also stimulated the phosphorylation of three mitogen-activated protein kinases (MAPKs: ERK, p38 MAPK and JNK) and Akt. Inhibition of ERK, p38 MAPK or JNK by specific inhibitors induced a dramatic reduction in Wnt5a-induced CCL2 production. Supernatant collected from lipopolysaccharide-stimulated macrophages induced neutrophil chemotaxis, which was significantly inhibited by anti-Wnt5a antibody. Our results suggested that Wnt5a may contribute to neutrophil recruitment, mediating the inflammation response.
		                        		
		                        		
		                        		
		                        			Activating Transcription Factor 2/metabolism
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Cell Separation
		                        			;
		                        		
		                        			Chemokines/*biosynthesis
		                        			;
		                        		
		                        			Chemotaxis/*drug effects
		                        			;
		                        		
		                        			Culture Media, Conditioned/pharmacology
		                        			;
		                        		
		                        			Extracellular Signal-Regulated MAP Kinases/metabolism
		                        			;
		                        		
		                        			GTP-Binding Proteins/metabolism
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			JNK Mitogen-Activated Protein Kinases/metabolism
		                        			;
		                        		
		                        			Lipopolysaccharides/pharmacology
		                        			;
		                        		
		                        			Macrophages/drug effects/metabolism
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			NF-kappa B/metabolism
		                        			;
		                        		
		                        			Neutrophils/*cytology/drug effects/enzymology/*metabolism
		                        			;
		                        		
		                        			Pertussis Toxin/pharmacology
		                        			;
		                        		
		                        			Phosphatidylinositol 3-Kinases/metabolism
		                        			;
		                        		
		                        			Proto-Oncogene Proteins c-akt/metabolism
		                        			;
		                        		
		                        			Receptors, Wnt/metabolism
		                        			;
		                        		
		                        			Type C Phospholipases/metabolism
		                        			;
		                        		
		                        			Wnt Proteins/*pharmacology
		                        			;
		                        		
		                        			p38 Mitogen-Activated Protein Kinases/metabolism
		                        			
		                        		
		                        	
2.Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Jae Heon JEONG ; Byoung Chul CHO ; Hyo Sup SHIM ; Hye Ryun KIM ; Sun Min LIM ; Se Kyu KIM ; Kyung Young CHUNG ; S M Bakhtiar Ul ISLAM ; Jae Jin SONG ; Soo Youl KIM ; Joo Hang KIM
Journal of Korean Medical Science 2013;28(7):1005-1014
		                        		
		                        			
		                        			Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-kappaB). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-kappaB expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-kappaB expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-kappaB value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinum-based doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; P=0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; P=0.013). Similarly, in EGFR wild-type patients treated with EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; P=0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI.
		                        		
		                        		
		                        		
		                        			Adenocarcinoma/*drug therapy/mortality/surgery
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Antineoplastic Agents/therapeutic use
		                        			;
		                        		
		                        			Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/surgery
		                        			;
		                        		
		                        			Disease-Free Survival
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			GTP-Binding Proteins/*biosynthesis
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lung Neoplasms/*drug therapy/mortality/surgery
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			NF-kappa B/biosynthesis
		                        			;
		                        		
		                        			Protein Kinase Inhibitors/therapeutic use
		                        			;
		                        		
		                        			Receptor, Epidermal Growth Factor/*antagonists & inhibitors/genetics
		                        			;
		                        		
		                        			Transglutaminases/*biosynthesis
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
3.Construction of recombinant lentiviral vectors containing Rheb gene and its mutant Rheb'D60K gene and their expression in human liver cancer cells.
Ke-He CHEN ; Bo LIANG ; Zhen-Hong ZOU ; Ze-Long HAN ; Jin-Fei PAN ; An-Ling LIU
Journal of Southern Medical University 2012;32(3):341-344
OBJECTIVETo construct recombinant lentiviral vectors carrying Rheb gene and its mutant Rheb'D60K gene, and examine their expression in human liver cancer cells.
METHODSRheb gene was amplified by PCR to construct the recombinant plasmid LV31-Rheb-WT and LV31-Rheb-D60K. HEK-293 FT cells were contransfected with the recombinant lentiviral vector together with a lentiviral package plasmid to produce the lentiviral particles. The expression of PS6 protein was detected in the lentivirus-infected MCF-7 cells. The apoptosis of SK-HEP-1 cells transfected with LV31-Rheb-WT or LV31-Rheb-D60K was observed.
RESULTSThe recombinant LV31-Rheb-WT and LV31-Rheb-D60K vectors were confirmed by PCR and DNA sequencing. Western blotting showed that PS6 protein expression was increased in LV31-Rheb-WT-transfected cells while decreased in LV31-Rheb-D60K-transfected cells. LV31-Rheb-D60K-transfected SK-HEP-1 cells showed more obvious apoptosis after starvation than LV31-Rheb-WT-transfected cells.
CONCLUSIONLentiviral vectors carrying Rheb gene and its mutant has been successfully constructed, which can be useful in further investigation of the role of Rheb gene in cancer cells.
Apoptosis ; genetics ; Carcinoma, Hepatocellular ; metabolism ; pathology ; Genetic Vectors ; genetics ; HEK293 Cells ; Humans ; Lentivirus ; genetics ; metabolism ; Liver Neoplasms ; metabolism ; pathology ; MCF-7 Cells ; Monomeric GTP-Binding Proteins ; biosynthesis ; genetics ; Mutant Proteins ; genetics ; Neuropeptides ; biosynthesis ; genetics ; Ras Homolog Enriched in Brain Protein ; Recombinant Proteins ; biosynthesis ; genetics ; Transfection
4.Construction and identification of Rac1-GTPase lentivirus.
Bin WANG ; Juan LI ; Lei ZHANG ; Lin ZHANG ; Lu ZHANG
Journal of Southern Medical University 2010;30(2):197-201
OBJECTIVETo construct lentiviruses carrying dominant negative mutant of Rac1-GTPase (Rac1N17) or the constitutive active mutant of Rac1-GTPase (Rac1L61) and expressing enhanced green fluorescent protein (EGFP) bicistronically.
METHODSThe lentiviral expression plasmid Plenti6/v5-Rac1N17 and Plenti6/v5-Rac1L61 were constructed and identified by restriction enzyme digestion and DNA sequence analysis. The two plasmids were packaged using the ViraPowerTM lentiviral expression system to produce replication-incompetent lentiviruses Rac1L61 and Rac1N17, which were used to infect the prefrontal cortex neurons (PFCs) from neonatal SD rats. The transfection efficiency and biological activity of different Rac1 mutants were evaluated and the morphology of the transfected PFCs was observed.
RESULTSThe results of DNA sequencing and restriction enzyme analysis demonstrated correct plasmid construction. The packaged lentiviral titer was 1x10(6) TU/ml. Analysis of Rac1 biological activity showed that Rac1N17 lentivirus particles infection significantly inhibited epidermal growth factor-stimulated Rac1 activity in the PFCs, while Rac1L61 lentivirus particles enhanced the Rac1 activity. The transfection efficiency of these Rac1 mutant lentivirus particles exceeded 80% in the PFCs. Morphologically, the PFCs exhibited distinct dendritic branches after infection by these lentiviruses.
CONCLUSIONThe lentiviruses carrying Rac1 dominant negative mutant and constitutive active mutant have been successfully constructed. The lentiviral particles can efficiently infect neonatal rat PFCs and lend important support for the study of Rac1-GTPase.
3T3 Cells ; Animals ; Animals, Newborn ; Cerebral Cortex ; cytology ; GTP Phosphohydrolases ; biosynthesis ; genetics ; Genetic Vectors ; genetics ; Green Fluorescent Proteins ; genetics ; metabolism ; Lentivirus ; genetics ; metabolism ; Mice ; Neurons ; metabolism ; physiology ; Rats ; Rats, Sprague-Dawley ; Recombinant Fusion Proteins ; biosynthesis ; genetics ; Signal Transduction ; Transfection ; rac1 GTP-Binding Protein ; biosynthesis ; genetics
5.Efficient fusion expression of G13 domain derived from granulysin in Escherichia coli.
Xiaoqiang LIU ; Xiangdong ZHA ; Yazhong XIAO ; Jinhuan YANG ; Nengshu LI
Chinese Journal of Biotechnology 2009;25(2):235-241
		                        		
		                        			
		                        			The G13 domain derived from granulysin shows high antimicrobial activities against Gram-positive and Gram-negative bacteria but does not lyse Jurkat cells or liposomes. To explore a new approach for high expression of the G13 domain, we fused the sequence encoding G13 to thioredoxin (Trx) gene to construct the recombinant expression vector (pThioHisA-G13). A cyanogen bromide (CNBr) cleavage site was introduced between the Trx and G13 to facilitate final release of the recombinant G13. The recombinant expression vector, pThioHisA-G13, was transformed into E. coli BL21 (DE3). Upon induction by IPTG Trx-G13 fusion protein was expressed and took the form of inclusion bodies counting 58% (W/W) of total cellular proteins. The inclusion body was solved by urea (8 mol/L) and then cleaved by CNBr. We purified the recombinant peptide G13 by one-step cation exchange chromatography. Results of agarose diffuse assay analysis indicated that the recombinant G13 exhibited antibacterial activity. The procedure described in this study will provide a reliable and simple method for highly efficient production of some cationic antimicrobial peptides.
		                        		
		                        		
		                        		
		                        			Anti-Infective Agents
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Antigens, Differentiation, T-Lymphocyte
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Cyanogen Bromide
		                        			;
		                        		
		                        			pharmacology
		                        			;
		                        		
		                        			Escherichia coli
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			GTP-Binding Protein alpha Subunits, G12-G13
		                        			;
		                        		
		                        			biosynthesis
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Inclusion Bodies
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Protein Structure, Tertiary
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Recombinant Fusion Proteins
		                        			;
		                        		
		                        			biosynthesis
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Thioredoxins
		                        			;
		                        		
		                        			genetics
		                        			;
		                        		
		                        			Transfection
		                        			
		                        		
		                        	
6.Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor.
Experimental & Molecular Medicine 2009;41(3):180-188
		                        		
		                        			
		                        			Tumor cells are known to produce larger amounts of reactive oxygen species (ROS) than normal cells. Although numerous reports have indicated the importance of ROS in urokinase plasminogen activator (uPA) production, the precise mechanisms remain controversial. In our study, we investigated the effect of ROS on uPA generation in human hepatoma cells, HepG2 and Hep 3B. We determined the effects of hepatocyte growth factor (HGF) on the regulation of ROS, which resulted in suppression of ROS production, as measured with the fluorescent probe, 2'-7'-dichlorofluorescein diacetate. The role of HGF in modulating ROS production, particularly that regulated by Rac-1, was determined. HGF suppressed the increment in Rac-1-regulated ROS in both cell lines. Treatment with 200 microM of H2O2 showed a 1.6-2.1 fold increment in HGF, but a little increment occurred at 500 microM of H2O2. It looks no dose dependent manner. Combined treatment with H2O2 and HGF, resulted in a slightly increased production of HGF compared to no treatment (control). Also, H2O2 upregulated uPA expression in both hepatoma cell lines. To identify the downstream pathways regulated by ROS, we treated cells with PD 98059, an MEK inhibitor, and SB 203580, a p38 inhibitor, after treatment with H2O2, and showed negative control between ERK and p38 kinase activities for uPA regulation. We found that HGF modulate Rac-1-regulated ROS production through activation of Akt and ROS regulates uPA production via MAP kinase, which provides a novel clue to clarify the mechanism underlying hepatoma progression.
		                        		
		                        		
		                        		
		                        			Cell Line, Tumor
		                        			;
		                        		
		                        			Fluorescent Dyes/chemistry
		                        			;
		                        		
		                        			Hepatocyte Growth Factor/pharmacology/*physiology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hydrogen Peroxide/pharmacology
		                        			;
		                        		
		                        			Imidazoles/pharmacology
		                        			;
		                        		
		                        			Liver Neoplasms/drug therapy
		                        			;
		                        		
		                        			Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism
		                        			;
		                        		
		                        			Pyridines/pharmacology
		                        			;
		                        		
		                        			Reactive Oxygen Species/*metabolism
		                        			;
		                        		
		                        			Recombinant Proteins/pharmacology
		                        			;
		                        		
		                        			Urokinase-Type Plasminogen Activator/*biosynthesis
		                        			;
		                        		
		                        			rac1 GTP-Binding Protein/metabolism
		                        			
		                        		
		                        	
7.Construction and identification of a eukaryotic expression vector for the small interfering RNA targeting nucleostemin gene.
Gong-yuan ZHANG ; Guo-qiang ZHAO ; Lei YIN ; Qin-xian ZHANG
Journal of Southern Medical University 2008;28(3):392-395
OBJECTIVETo construct a eukaryotic expression vector for the small interfering RNA (siRNA) targeting nucleostemin (NS) gene.
METHODSThe siRNA targeting NS gene was designed according to the sequence of NS mRNA available in GenBank. Three siRNA sequences were obtained, and the corresponding cDNAs were synthesized and inserted into plasmid pRNAT-U6.1 for constructing the recombinant plasmids, which were transformed into E.coli DH5alpha strain. The plasmids, after identification by PCR and DNA sequencing, were transfected into EC9706 cell line via liposome, and the mRNA and protein expressions of NS gene in the cells were determined by RT-PCR and Western blotting, respectively.
RESULTSThree recombinant plasmids were identified by PCR and sequence analysis, the results of which showed correct insertion of the designed sequences in the plasmids. RT-PCR and Western blotting showed substantially decreased mRNA and protein expressions of NS gene in the transfected cells.
CONCLUSIONThe recombinant plasmid expressing the siRNA targeting NS gene has been successfully constructed, which provides the basis for studying RNA interference of the NS gene.
Base Sequence ; Blotting, Western ; Carrier Proteins ; biosynthesis ; genetics ; Cell Line ; Cloning, Molecular ; Eukaryotic Cells ; metabolism ; GTP-Binding Proteins ; Genetic Vectors ; genetics ; Humans ; Molecular Sequence Data ; Nuclear Proteins ; biosynthesis ; genetics ; Oligonucleotide Array Sequence Analysis ; RNA Interference ; RNA, Messenger ; biosynthesis ; genetics ; RNA, Small Interfering ; genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Transfection
8.Expression of nucleostemin in prostate cancer tissues and its clinical significance.
Ran-Lu LIU ; Yong XU ; Zhi-Hong ZHANG ; Meng WANG ; Jian-Tao SUN ; Shi-Yong QI ; Yue ZHANG ; Sheng-Zhi LI
National Journal of Andrology 2008;14(5):418-422
OBJECTIVETo explore the expression of the nucleostemin (NS) gene in prostate cancer (PCa) tissues and its clinical significance.
METHODSWe detected the NS expression in PCa, benign prostatic hyperplasia (BPH) and high grade prostatic intraepithelial neoplasia (HGPIN) tissues by RT-PCR and immunohistochemistry, and analyzed the correlation between the expression of the NS protein and the clinical variables of PCa.
RESULTSThe NS mRNA level was markedly higher in the PCa than in the BPH tissues. The rates of strongly positive, positive and weakly positive expressions of the NS protein were 48.8%, 36.6% and 12.2% in PCa, 4.0%, 32.0% and 56.0% in BPH, and 5.0%, 25.0% and 60.0% in HGPIN, respectively. The expression level of the NS protein was significantly higher in PCa than in BPH and HGPIN (P < 0.05). The expression of the NS gene was negatively correlated with the degree of cell differentiation in the PCa tissues, the worse the differentiation, the higher the NS expression level.
CONCLUSIONThe NS gene is highly expressed in PCa tissues and may have an important role in the adverse differentiation and malignant proliferation of prostate cancer.
Aged ; Carrier Proteins ; biosynthesis ; genetics ; GTP-Binding Proteins ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Neoplasm Staging ; Nuclear Proteins ; biosynthesis ; genetics ; Prostatic Neoplasms ; genetics ; metabolism ; pathology ; RNA, Messenger ; genetics ; metabolism ; Reverse Transcriptase Polymerase Chain Reaction
9.Expression of nucleostemin mRNA and protein in the esophageal squamous cell carcinoma.
Gong-Yuan ZHANG ; Lei YIN ; Sheng-Lei LI ; Wen-Ying XING ; Qiu-Min ZHAO ; Xiao-Ping LE ; Dong-Ling GAO ; Kui-Sheng CHEN ; Yun-Han ZHANG ; Qin-Xian ZHANG
Chinese Journal of Oncology 2008;30(2):125-128
OBJECTIVETo investigate the mRNA and protein expression of nucleostemin (NS) in human esophageal squamous cell carcinoma.
METHODSThe mRNA and protein expression of NS were detected in 31 mucosal atypical hyperplasia specimens, 62 esophageal squamous cell carcinoma specimens and the matched normal esophageal mucosa samples by RT-PCR and immunohistochemistry method, respectively.
RESULTSThe positive expression rate of NS protein in normal esophageal mucosa, atypical hyperplasia and esophageal squamous cell carcinoma was 17.7% (11/62), 41.9% (13/31) and 69.4% (43/62), respectively. There was a significant difference among the above three groups (chi2 = 33.676, P < 0.01). The expression levels of NS mRNA in esophageal squamous cell carcinoma (0.971 +/- 0.121) was significantly higher than that in the atypical hyperplasia (0.913 +/- 0.085) and also in the normal esophageal mucosa (0.866 +/- 0.103; F = 14.829, P < 0.01). The expression level of both NS protein and mRNA was positively correlated with histological grade, infiltration depth, and lymph node metastasis (P < 0.05), but not with age, gender or pathological type (P > 0.05).
CONCLUSIONOur results indicate that nucleostemin mRNA and protein are over-expressed in human esophageal squamous cell carcinoma, and it may be related with its oncogenesis.
Carcinoma, Squamous Cell ; metabolism ; pathology ; Carrier Proteins ; biosynthesis ; genetics ; Esophageal Neoplasms ; metabolism ; pathology ; Esophagus ; pathology ; Female ; GTP-Binding Proteins ; Gene Expression Regulation, Neoplastic ; Humans ; Hyperplasia ; Lymphatic Metastasis ; Male ; Middle Aged ; Mucous Membrane ; metabolism ; Neoplasm Invasiveness ; Neoplasm Staging ; Nuclear Proteins ; biosynthesis ; genetics ; Precancerous Conditions ; metabolism ; pathology ; RNA, Messenger ; metabolism
10.Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells.
Kang Jin JEONG ; Soon Young PARK ; Ji Hye SEO ; Kyung Bok LEE ; Wahn Soo CHOI ; Jeung Whan HAN ; Jae Ku KANG ; Chang Gyo PARK ; Yong Kee KIM ; Hoi Young LEE
Experimental & Molecular Medicine 2008;40(6):607-616
		                        		
		                        			
		                        			Lysophosphatidic acid (LPA) is a bioactive phospholipids and involves in various cellular events, including tumor cell migration. In the present study, we investigated LPA receptor and its transactivation to EGFR for cyclooxygenase-2 (COX-2) expression and cell migration in CAOV-3 ovarian cancer cells. LPA induced COX-2 expression in a dose-dependent manner, and pretreatment of the cells with pharmacological inhibitors of Gi (pertussis toxin), Src (PP2), EGF receptor (EGFR) (AG1478), ERK (PD98059) significantly inhibited LPA- induced COX-2 expression. Consistent to these results, transfection of the cells with selective Src siRNA attenuated COX-2 expression by LPA. LPA stimulated CAOV-3 cell migration that was abrogated by pharmacological inhibitors and antibody of EP2. Higher expression of LPA2 mRNA was observed in CAOV-3 cells, and transfection of the cells with a selective LPA2 siRNA significantly inhibited LPA-induced activation of EGFR and ERK, as well as COX-2 expression. Importantly, LPA2 siRNA also blocked LPA-induced ovarian cancer cell migration. Collectively, our results clearly show the significance of LPA2 and Gi/Src pathway for LPA-induced COX-2 expression and cell migration that could be a promising drug target for ovarian cancer cell metastasis.
		                        		
		                        		
		                        		
		                        			Butadienes/pharmacology
		                        			;
		                        		
		                        			Cell Line, Tumor
		                        			;
		                        		
		                        			Cell Movement/drug effects/*physiology
		                        			;
		                        		
		                        			Cyclooxygenase 2/*biosynthesis
		                        			;
		                        		
		                        			Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors/metabolism
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Flavonoids/pharmacology
		                        			;
		                        		
		                        			GTP-Binding Protein alpha Subunits, Gi-Go/antagonists & inhibitors/*metabolism
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lysophospholipids/pharmacology
		                        			;
		                        		
		                        			Nitriles/pharmacology
		                        			;
		                        		
		                        			Ovarian Neoplasms/metabolism/*pathology
		                        			;
		                        		
		                        			Pertussis Toxin/pharmacology
		                        			;
		                        		
		                        			Protein-Tyrosine Kinases/antagonists & inhibitors/*metabolism
		                        			;
		                        		
		                        			Proto-Oncogene Proteins/antagonists & inhibitors/*metabolism
		                        			;
		                        		
		                        			Pyrimidines/pharmacology
		                        			;
		                        		
		                        			Receptor, Epidermal Growth Factor/antagonists & inhibitors/metabolism
		                        			;
		                        		
		                        			Receptors, Lysophosphatidic Acid/*metabolism
		                        			;
		                        		
		                        			Receptors, Prostaglandin E/metabolism
		                        			;
		                        		
		                        			Signal Transduction
		                        			;
		                        		
		                        			Transcriptional Activation
		                        			;
		                        		
		                        			Tyrphostins/pharmacology
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail